Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B2 alpelisib maintenance in PIK3CA-mutant HER2-positive advanced breast cancer
NL-OMON52551Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpelisib in breast cancer (3 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities and Progression-free survival. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52551.